Tyrell J. Rivers
Director/Board Member chez ADC THERAPEUTICS SA
Profil
Tyrell J.
Rivers is currently an Executive Director-Corporate Development at AstraZeneca PLC, a Director at Cerapedics, Inc., an Independent Non-Executive Director at ADC Therapeutics SA, and a Director at Biohealth Innovation, Inc., Corvidia Therapeutics, Inc., and VaxEquity Ltd.
Rivers has previously worked as a Senior Associate at MedImmune Ventures, Inc. and held director positions at PhaseBio Pharmaceuticals, Inc., Armaron Bio Ltd., G1 Therapeutics, Inc., Goldfinch Bio, Inc., and Viela Bio, Inc. Rivers has an undergraduate degree from Massachusetts Institute of Technology, a graduate degree and doctorate from The University of Texas at Austin, and an MBA from The Leonard N Stern School of Business.
Postes actifs de Tyrell J. Rivers
| Sociétés | Poste | Début |
|---|---|---|
| ADC THERAPEUTICS SA | Director/Board Member | 01/06/2018 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2014 |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Director/Board Member | - |
Cerapedics, Inc.
 Cerapedics, Inc. Pharmaceuticals: MajorHealth Technology Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO. | Director/Board Member | - |
Biohealth Innovation, Inc.
 Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Director/Board Member | - |
VaxEquity Ltd.
 VaxEquity Ltd. BiotechnologyHealth Technology VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. | Director/Board Member | - |
Anciens postes connus de Tyrell J. Rivers
| Sociétés | Poste | Fin |
|---|---|---|
| VIELA BIO, INC. | Director/Board Member | 15/03/2021 |
| PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 17/10/2018 |
| G1 THERAPEUTICS, INC. | Director/Board Member | 30/06/2018 |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Tyrell J. Rivers
| Massachusetts Institute of Technology | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
| G1 THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures, Inc. ( Medimmune Ventures) is a venture capital firm founded in 2002 by Ron Laufer, Wayne Hockmeyer and David Mott . The firm is headquartered in Gaithersburg, Maryland. | Finance |
Cerapedics, Inc.
Cerapedics, Inc. Pharmaceuticals: MajorHealth Technology Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO. | Health Technology |
Armaron Bio Ltd.
 Armaron Bio Ltd. Electronic Equipment/InstrumentsElectronic Technology Armaron Bio Ltd. operates a clinical stage biotechnology firm. It discovers, develops, and commercializes proprietary molecules to prevent heart failure, diabetes, and other serious diseases. The company is headquartered in Melbourne, Australia. | Electronic Technology |
Biohealth Innovation, Inc.
Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Finance |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
VaxEquity Ltd.
VaxEquity Ltd. BiotechnologyHealth Technology VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. | Health Technology |
